British patients with type 1 diabetes were enrolled in group training courses that taught flexible intensive insulin treatment and then randomized to an insulin pump or multiple daily injections and followed for two years.
Clinicians should be aware of the strengths and weaknesses of diabetes apps and be able to advise patients on their use, according to the European Association for the Study of Diabetes and the American Diabetes Association.
The frequency of diabetes visits varied across health systems, but within most of the studied organizations, patients with high HbA1c levels were not seen any more often than those with lower levels.
The trial of semaglutide included 3,297 patients with type 2 diabetes, 83% of whom had established cardiovascular disease, chronic kidney disease, or both.
The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which was funded by Novo Nordisk and the National Institutes of Health, randomized 9,340 patients ages 50 years and older to 1.8 mg of
Patients with type 1 diabetes who were randomly assigned to insulin treatment with a closed-loop system spent more time in the target glycemic range than those assigned to a sensor-augmented pump.
A narrative review considered the available evidence on use of metformin, thiazolidinediones, sulfonylureas, sodium-glucose cotransporter-2 inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors in the hospital.
Randomized trial participants with type 1 diabetes and mild-to-moderate diabetic kidney disease who received allopurinol or placebo had similar estimated glomerular filtration rates after three years.
Real-time continuous glucose monitoring (CGM), with either an insulin pump or multiple daily injections, was associated with sustained improvements in HbA1c levels compared to self-monitoring of blood glucose, according to a small randomized trial.
In a longitudinal study of 21,531 patients, those in poor or intermediate health at age 75 years were more likely to use insulin than those in good health (29.4% and 27.5% versus 10.5%, respectively) and less likely to discontinue it during follow-up